CAMBRIDGE, Mass., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR ), a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal rare diseases, announced that the Company will host an Analyst and Investor Day on Thursday, November 7, 2013 from 2:00pm to 5:00pm in New York City. Members of Aegerion's management team will provide an overview of the Company's vision, strategy, business trends, commercial launch traction, addressable market, regulatory progress and clinical plans. In addition, a prescribing cardiologist will discuss his experience with the Company's product, JUXTAPID®.
The event will be webcast live, and may be accessed by visiting the "Investors" section of the Company's website, www.aegerion.com . Interested parties unable to join the live call may access an archived version of the webcast on Aegerion's website for 30 days following the event.
About Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com .
Aegerion Pharmaceuticals, Inc. Amanda Murphy, Manager, IR 857-242-5024
